

Day 1: Wednesday 09 December 2020

Time	Subject	Presenter(s)
07:15	Log on to Zoom	
07:30	Welcome	Peter Billingsley
07:35	Introduction and Overview of the Meeting	Stephen Hoffman
07:45	In Memory of Dra. Angelines Nnang Eyene Nchama	Vicente Urbano, Wonder Phiri
07:48	Opening remarks	Peter Kreamsner, Alassane Dicko, H.E. Diosdado Milang (Minister of Health, EG)
Pathway to licensure for PfSPZ Vaccine		
07:58	Overview of Sanaria strategy	Thomas Richie
08:18	Safety endpoint: Meta analysis of PfSPZ Vaccine safety	Preston Church
08:23	Malaria endpoint: PCR with validated biomarkers	Sean Murphy
08:28	Malaria endpoint: Validation of the Thick Blood Smear Assay for clinical endpoint	Pete Billingsley
08:33	Manufacturing for Phase 3 and licensure	Kim Lee Sim
08:38	Progress with and timelines for FDA and EMA submissions	Tooba Murshedkar
Status of planned trials with Phase 3 PfSPZ Vaccine		
08:43	Warfighter 3	Preston Church
08:48	TravSPZV1	Peter Kreamsner, Judith Epstein
08:53	EGSPZV4	Said Jongo, Raul Chuquiyaui
09:03	Discussion	Moderators: Patrick Duffy, Michael Good
Ongoing and proposed additional clinical trials of PfSPZ Vaccine		
09:23	Mali 4 vaccine efficacy	Halimatou Diawara
09:30	LaSPZV1	Maxime Agnandji, Preston Church
09:37	Indonesia	Erni Nelwan
09:44	Seasonal vaccination of children	Stephen Hoffman
09:49	Discussion	Moderators: Tina Oneko
10:00	Burkina Faso - 18 month vaccine efficacy	Sodiomon Sirima, Matthew Laurens
Developing a vaccine for Women of Child Bearing Potential (WOCB)		
10:07	General overview	Sara Healy
10:12	Summary of second expert meeting	Judith Epstein
10:22	Reproductive toxicology of PfSPZ Vaccine in pregnant rabbits	Pete Billingsley
10:27	Mali 4 pregnancy outcomes	Halimatou Diawara
10:32	Clinical development plan for PfSPZ Vaccine to prevent pregnancy malaria	Halimatou Diawara, Patrick Duffy
10:37	Discussion	Moderators: Judy Epstein, Blair Wylie
10:52	Coffee	
The funders perspective		
11:02	Introduction and overview	Stephen Hoffman
11:10	The EU Malaria Fund	Holm Keller
11:15	NIAID-NIH	Lee Hall
11:20	Government of Equatorial Guinea and energy companies	Mitoha Ondo'o Ayekaba, Bonifacio Manguire
11:25	EDCTP	Pauline Beattie
11:30	Prince Ned Nwoko Malaria Eradication Project	Prince Ned Nwoko/Anyaduba Chuks
11:35	Discussion	Moderators: Peter Kreamsner, Stephen Hoffman
New developments and directions with CHMI		
11:45	Introduction	Thomas Richie
11:50	Establishing CHMI as a surrogate for natural exposure in Africa (Pf7G8) and globally (which Pf strains?)	Joana Silva
12:00	Update of 160 CHMIs in Kilifi	Melissa Kapulu
12:10	Repeat CHMI (PfSPZ Challenge NF54) in semi-immune Tanzanians demonstrates boosting of naturally acquired immunity	Tobias Schindler
12:15	Using repeated CHMI with PfSPZ Challenge (NF54/7G8) in Gabon to understand development of adaptive immunity	Matthew McCall, Maxime Agnandji
12:23	Expansion of functional myeloid-derived suppressor cells in controlled human malaria infection	Carlos Lamsfus Calle, Rolf Fendel
12:28	Moving closer to PvSPZ Challenge	Sumana Chakravarty
12:33	Update on cardiac events after mosquito bite-induced Pf infection and treatment in Nijmegen	Matthew McCall
12:38	Discussion	Moderators: Benjamin Mordmüller, Meta Roestenberg, Said Jongo
12:53	Closing remarks	Stephen Hoffman



International PfSPZ Consortium Meeting

Day 2: Thursday 10 December 2020

Time	Subject	Presenter
07:15	Log on to Zoom	
07:30	Introduction to the day	Stephen Hoffman
	PfSPZ-CVac Current and Planned Trials	
07:35	Overview of PfSPZ-CVac clinical development plan	Thomas Richie
07:40	PfSPZ-CVac (PYR/CQ) - results of LMIV clinical trials focusing on heterologous CHMI at 12-13 weeks	David Cook
07:47	PfSPZ-CVac (PYR/CQ) - field trial in adults in Mali	Issaka Sagara, David Cook
07:57	TÜCHMI-003 results, day 1, 6, and 29 regimen heterologous CHMI at 12.5 weeks	Rolf Fendel
08:07	Plans for use of pyronaridine for PfSPZ-CVac in Tuebingen and Africa	Andrea Kreidenweiss, Sodiomon Sirima
08:14	Development of PfSPZ-CVac in children	Stephen Hoffman
08:21	Discussion: the future pathway for PfSPZ-CVac	Moderators: Patrick Duffy
	Progress with genetically altered SPZ vaccines	
08:41	Late-arresting, replication competent (LARC), genetically attenuated parasite (GAP) vaccines: progress and long term strategy	Stefan Kappe
08:51	Plans and timeline for new phase 1 facility: first product PfSPZ-LARC1	Kim Lee Sim
08:56	Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite (U01)	Kim Lee Sim, Ashley Vaughan
09:03	Development of Pf expressing heterologous proteins (e.g. PvCSP)	Blandine Franke-Fayard
09:10	Biologically informed design of CD8+ T cell-dependent Pre-erythrocytic stage malaria vaccines	Debashree Goswami
09:17	Discussion	Moderators: Stefan Kappe, Chris Janse
09:32	Coffee	
	In vitro PfSPZ	
09:47	Opening comments	Stephen Hoffman
09:52	Molecular markers for PfSPZ development <i>in vitro</i>	Ashley Vaughan
10:02	<i>In vitro</i> production of PfSPZ	Abraham Eappen
10:12	Discussion	Moderators: Alon Warburg, Photini Sinnis
	Immunology 1: data from recent studies	
10:22	Updates from LMIV with focus on V δ 2 $\gamma\delta$ T cells	Bob Morrison, Irfan Zaidi, Patrick Duffy
10:32	Updates on immunological studies in Tanzania and Equatorial Guinea	Claudia Daubenberger
10:40	New data on IgA antibodies to PfCSP	Joshua Tan
10:48	New insights into protective responses after PfSPZ immunization of Kenyan infants	Tuan Tran
10:56	Discussion	Moderators: Claudia Daubenberger, John Tsang
	Immunology 2: using immunology to better understand and harness protective immunity	
11:06	Immunization of rhesus macaques with irr PkSPZ with and without GMP-manufactured 7DW8-5 adjuvant	Sumana Chakravarty, Moriya Tsuji
11:14	Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ Vaccines (U01)	Sumana Chakravarty
11:22	Systems serology	Galit Alter
11:32	Systems immunology	John Tsang
11:40	Update from Seattle	Ken Stuart
11:45	New U01 call: Multidisciplinary Approach to Study Vaccine-elicited Immunity and Efficacy against Malaria	Annie Mo
11:53	Discussion of potential proposals for new U01 call	Stephen Hoffman
12:01	Discussion	Moderators: Annie Mo, Sean Murphy
	Eyes on the prize: considerations for deployment for eventual elimination	
12:14	Introduction	Thomas Richie
12:17	Context setting 1:	Pedro Alonso
12:22	Context setting 2:	Marcel Tanner
12:27	Integrating malaria control and vaccine deployment for elimination	Salim Abdulla
12:32	Demonstrating focal elimination - thoughts for a Tanzanian context	Honorati Masanja
12:37	Using EGMVI-developed infrastructure to tackle COVID-19	Max Mpina, Claudia Daubenberger
12:42	Discussion: How best to use PfSPZ vaccines in a public health setting	Moderators: Marcel Tanner, Fred Binka
	Close out session	
12:52	General discussion: consortium priorities for 2021	Pete Billingsley
13:07	Final remarks	Stephen Hoffman